Medical devices, healthcare technology and the business of care
FDA RECALL RECORD · Z-2322-2025

Access Thyroglobulin assay, a simultaneous one-step immunoenzymatic assay, Catalog Number 33860 Recall

Access Thyroglobulin assay, a simultaneous one-step immunoenzymatic assay, Catalog Number 33860

FDA recall Class II

Ongoing

FDA lists this Class II recall for Access Thyroglobulin assay, a simultaneous one-step immunoenzymatic assay, Catalog Number 33860. Review the affected identifiers, reported reason and manufacturer instructions below.

Recall at a glance

Recall number
Z-2322-2025
Recall classification
Class II
Enforcement status
Ongoing
Initiation date
Jul 10, 2025
FDA report date
Aug 20, 2025
Quantity in commerce
453 units
Distribution
See key details
FDA cause
Under Investigation by firm

What is being recalled?

Access Thyroglobulin assay, a simultaneous one-step immunoenzymatic assay, Catalog Number 33860

Affected model & UDI checker

Search the exact identifiers published for Z-2322-2025.

The lookup covers structured identifiers listed on this page. A full UDI may also contain lot or serial information; a GTIN match alone does not check those conditions.

Affected products

Model / catalog numberProductLot scope reportedUDI / GTIN
33860Access Thyroglobulin assay, a simultaneous one-step immunoenzymatic assay, Catalog Number 33860Check source noticeNot specified
Not specifiedAccess Thyroglobulin assay, a simultaneous one-step immunoenzymatic assay, Catalog Number 33860Check source notice15099590227173
FDA code information

UDI-DI: 15099590227173; Lot Number: 439163

View the original FDA recall notice

Why was this product recalled?

Access Thyroglobulin reagent lot 439163 may generate erroneously high patient results. Falsely increased Access Thyroglobulin results may lead a physician to pursue unnecessary diagnostic imaging studies and/or inappropriate therapy adjustments in patients being monitored for residual or recurrent thyroid cancer.

What actions did BECKMAN COULTER, INC. take?

An URGENT MEDICAL DEVICE RECALL notification dated 7/2/25 was sent to customers. ACTION: " Discontinue using Access Thyroglobulin reagent lot 439163 and discard all remaining reagent packs from this lot. " At the discretion of the medical director, a retrospective review of patient results generated with Access Thyroglobulin reagent lot 439163 should be performed, which includes reviewing patient history, to assess the need for retesting. " Please contact your local Beckman Coulter representative for replacement product requests and to receive updates on availability and delivery. RESOLUTION: Beckman Coulter is investigating the root cause of this issue to prevent similar occurrences. Please share this information with your laboratory staff and retain this notification as part of your laboratory Quality System documentation. If you have forwarded any of the affected product listed above to another laboratory, please provide them a copy of this letter. So that we are assured you have received this important communication, please respond within 10 days in one of the following ways: " Electronically, if you received this communication via email. " Manually, complete and return the enclosed Response Form. If you have any questions regarding this notice, please contact our Customer Support Center: " From our website: http://www.beckmancoulter.com " Contact your local Beckman Coulter Representative for replacement.

Read the manufacturer action recorded by FDA

Recall timeline

  1. Recall initiated by firm

  2. FDA notice posted

  3. FDA classification recorded

  4. FDA enforcement report date

Related FDA submissions

No submission number with an exact verified relationship is linked in the retrieved recall notice.

FDA’s notice explicitly links the submission numbers shown here. Read each filing for its own recorded device and scope.

Source and update history

  1. FDA enforcement data

    First stored snapshot of this source.

  2. FDA device-recall notice

    First stored snapshot of this source.

The history starts with the versions held by MedtechLedger. Earlier source changes are not reconstructed. Official dates and recorded status come from FDA; page summaries describe the source information.

Our data sources and methodology